Macquarie Group
CSBR icon

Macquarie Group’s Champions Oncology CSBR Stock Holding History

Macquarie Group’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-900
Closed -$7K – 1720
2018
Q4 		$7K Buy
+900
New +$10.3K ﹤0.01% 1989

Other funds holding CSBR

BPI
Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Macquarie Group's CSBR Position: Q1 2019 in Review

Macquarie Group sold out of Champions Oncology (CSBR) in Q1 2019, closing a stake of 900 shares — an estimated $7K sold.

Macquarie Group first reported a position in CSBR in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 38 funds tracked by Wall St. Rank hold CSBR as of Q1 2019.

  • Macquarie Group reported no remaining Champions Oncology position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 900 Champions Oncology shares in Q1 2019, an estimated $7K.
  • Macquarie Group first reported a position in Champions Oncology in Q4 2018 and held it in 1 quarter.
  • Macquarie Group's Champions Oncology position peaked at $7K in Q4 2018.
  • 38 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.